S. Pouzieux

SAR650984, A Novel Humanized CD38-Targeting Antibody, Demonstrates Potent Antitumor Activity in Models of Multiple Myeloma and Other CD38+ Hematologic Malignancies

J. Deckert, T. Chittenden, A. Plesa, 2014, Clinical Cancer Research.

A single T cell epitope drives the neutralizing anti-drug antibody response to natalizumab in multiple sclerosis patients

R. Geiger, D. Jarrossay, F. Sallusto, 2019, Nature Medicine.

Crystal structures of human factor Xa complexed with potent inhibitors.

A. Spada, W. R. Ewing, V. Mikol, 2000, Journal of medicinal chemistry.

SAR156497, an exquisitely selective inhibitor of aurora kinases.

Sébastien Maignan, François Clerc, Thomas Bertrand, 2014, Journal of medicinal chemistry.

Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming

Laurence Zitvogel, Sebastian Amigorena, Florence Faure, 2001, Nature Medicine.

Trispecific antibodies enhance the therapeutic efficacy of tumor-directed T cells through T cell receptor co-stimulation

G. Nabel, M. Chiron, Huawei Qiu, 2019, Nature Cancer.

Albumin binding Nanofitins, a new scaffold to extend half-life of biologics – a case study with exenatide peptide

M. Cinier, N. Michot, J. Dumas, 2022, Peptides.

SAR650984, A Novel Humanized CD38-Targeting Antibody, Demonstrates Potent Antitumor Activity in Models of Multiple Myeloma and Other CD38+ Hematologic Malignancies

T. Chittenden, A. Plesa, M. Chiron, 2014, Clinical Cancer Research.